52W $0.50 – $6.06
Oragenics, Inc.
Revenue breakdown: Grant (100%).
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. As previously disclosed, on October 11, 2024, Oragenics, Inc. (the “ Company ”) entered into an At-the-Market Sales
. FINANCIAL STATEMENTS AND EXHIBITS.** (d) Exhibits | Exhibit No. | | Description | |---|---|---| | | | | | 104 | | Cover page Interactive Data File (embedded i
. OTHER INFORMATION. On March 10, 2026, Oragenics, Inc. (the “Company”) issued a press release announcing that it had received final Human Research Ethics Commi
of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amen
Revenue by Segment